

The CCS is committed to preserving the scientific integrity of its Guidelines and Clinical Practice Updates through transparency and management of disclosures (industry, academic, financial benefits and other conflicts). Invited and approved panel members must disclose all relationships regardless of relevance to the topic. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit [www.ccs.ca](http://www.ccs.ca). Updated March 8, 2023.

Affiliations with commercial organizations or clinical trials within the previous two years that may have a direct or indirect connection to the content of this statement are disclosed here.

Writing Panel Members		Consulting Fees / Honoraria	Clinical Trials	Other Financial Benefits	Relevance to Statement
First name	Last name				
Melanie	Care	None	None	None	None
Zachary	Laksman	None	None	None	None
Laura A.	Arbour	None	None	None	None
Liam	Brunham	Amgen, Novartis, HLS, Ultragenyx, Astra Zeneca, Merck	Amgen, Novartis, Eli Lilly, Astra Zeneca, Ionis, Verve	None	These consulting relationships have no relation to the clinical practice update topic or scope.
Susan	Christian	None	None	AstraZeneca, Pfizer	Education grants received 2023-2024 unrelated to the clinical practice update topic or scope.
Johannie	Gagnon	None	None	None	None
Robert	Hegele	Amgen, Novartis, Pfizer, Sanofi, Akcea-Ionis, Arrowhead, HLS Therapeutics, Medison, Regeneron, UltraGenyx	Amryt, Arrowhead, Astra Zeneca		These have no relationship to the clinical implementation of Cardiogenetics CPU.
Rebekah	Jobling	None	None	None	None
Gavin Y.	Oudit	Bristol-Myers Squibb, Sanofi, Takeda	None	None	These consulting relationships have no relation to the clinical practice update topic or scope.